Table 1.
RS frequency in patients treated with therapeutic regimens based on pathway inhibitors.
| Number of CLL Patients | Study Population | Treatment | RS Prevalence (%) | Reference |
|---|---|---|---|---|
| 391 | Relapsed | Ibrutinib, ofatumumab | 1 | Byrd, 2014 [23] |
| 29 | Progressive untreated | Ibrutinib | 3 | O’Brien, 2014 [24] |
| 194 | R/R | Venetoclax-rituximab | 3 | Seymour, 2018 [19] |
| 127 | R/R | Ibrutinib | 5 | Jain, 2015 [25] |
| 84 | 17p deleted or ≥65 years | Ibrutinib | 6 | Ahn, 2017 [21] |
| 358 | Treatment-naïve | Acalabrutinib, Obinutuzumab | 2 | Sharman, 2020 [18] |
| 51 | 17p deleted | Ibrutinib | 6 | Farooqui, 2015 [26] |
| 178 | BCRi treated | Ibrutinib, idelalisib | 7 | Mato, 2016 [27] |
| 113 | Treatment-naïve | Ibrutinib-obinutuzumab | 0 | Moreno, 2019 [17] |
| 85 | R/R | Ibrutinib | 8 | Byrd, 2013 [28] |
| 116 | R/R | Venetoclax | 16 | Roberts, 2016 [29] |
| 67 | R/R, 17p deleted | Venetoclax | 25 | Anderson, 2017 [30] |
| 2975 | R/R | B, F, C, Clb, rituximab, obinutuzumab, ibrutinib, venetoclax | 3 | Al-Sawaf, 2021 [15] |
| 195 | R/R | Ibrutinib | 10 | Munir, 2019 [20] |
Abbreviations: RS, Richter Syndrome; R/R, relapsed/refractory; BCRi, B-cell receptor pathway inhibitors; B, bendamustine; F, fludarabine; C, cyclophosphamide; Clb, chlorambucil.